P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

MLA

Hermann Einsele, et al. “P923: Comparative Effectiveness of Talquetamab Vs Real-World Physician’s Choice of Treatment in Locommotion and Momment for Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.” HemaSphere, vol. 7, Aug. 2023, p. e5183528. EBSCOhost, https://doi.org/10.1097/01.HS9.0000970596.51835.28.

APA

Hermann Einsele, Philippe Moreau, Nizar J Bahlis, Manisha Bhutani, Laure Vincent, Lionel Karlin, Aurore Perrot, Hartmut Goldschmidt, Niels W.C.J. van de Donk, Enrique Ocio, Joaquín Martinez-Lopez, Paula Rodríguez-Otero, Dominik Dytfeld, Joris Diels, Vadim Strulev, Imene Haddad, Thomas Renaud, Eric Ammann, Jedelyn Cabrieto, … Maria-Victoria Mateos. (2023). P923: Comparative Effectiveness of Talquetamab Vs Real-World Physician’s Choice of Treatment in Locommotion and Momment for Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. HemaSphere, 7, e5183528. https://doi.org/10.1097/01.HS9.0000970596.51835.28

Chicago

Hermann Einsele, Philippe Moreau, Nizar J Bahlis, Manisha Bhutani, Laure Vincent, Lionel Karlin, Aurore Perrot, et al. 2023. “P923: Comparative Effectiveness of Talquetamab Vs Real-World Physician’s Choice of Treatment in Locommotion and Momment for Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.” HemaSphere 7 (August): e5183528. doi:10.1097/01.HS9.0000970596.51835.28.